Inactivation of TGF-β/SMAD4 signaling was postulated to play an important role in breast cancer development. Even though SMAD4 is located on 18q21, a region frequently lost in breast cancers, point mutations of SMAD4 were rarely observed, implying that biallelic inactivation of SMAD4 was not necessary in the process. In this study, a novel homozygous deletion of SMAD4 was identified in breast cancer cell line SW527 during a screening of 31 breast cancer cell lines. As several breast cancer cell lines were shown to contain SMAD4 homozygous deletion, we sought to develop a reliable method to access such lesions in archived primary tumor specimens. First, a DNA quantification method was developed to measure as few as 5 copies of DNA templates so that the amount of genomic DNA isolated by laser-capture microdissection can be accurately determined. Next, accurate DNA quantitation allowed sufficient DNA templates to be included in the homozygous deletion assay for the robust amplification of SMAD4 genetic markers. Two out of 24 primary infiltrative ductal carcinomas (IDC) with 18q allelic imbalance were determined to contain SMAD4 homozygous deletions, and these samples are also negative for Smad4 protein expression by immunohistochemistry. Our data suggest that biallelic inactivation of SMAD4 through homozygous deletion does occur in a small percentage of IDCs, and support the hypothesis that inactivation of TGF-β/SMAD4 signaling plays in a role in the development of a subset of IDC.
INTRODUCTION
Breast cancer is the most frequently diagnosed neoplasia and the second leading cause of cancer deaths in American women. 1 Infiltrating ductal carcinoma (IDC) is the most common subtypes of breast cancer, accounting for 80% of all patients. Like other types of solid tumors, the breast cancer genome is not stable, and such genomic instability leads to the activation of oncogenes and the inactivation of tumor suppressor genes, both of which are required for the initiation and progression of this cancer. Loss of heterozygosity (LOH) analysis has been used to screen for genomic regions in breast tumor that are frequently altered, and one of the most commonly lost region is located on chromosome 18q. 2 Since LOH is commonly associated with the inactivation of tumor suppressor genes, these evidences suggest the presence of one or several tumor suppressor gene(s) on 18q, whose inactivation is required for mammary tumorigenesis.
One candidate tumor suppressor gene is SMAD4 (a.k.a. MADH4/DPC4) located on 18q21, and it acts as a convergent node in the TGF-β signaling pathway. TGF-β signaling pathway comprises of signaling molecules (TGF-β and BMPs), receptors (TβRI and TβRII receptors) and Smads. The binding of signaling molecules to the receptors leads to activation of Smads. Smad4 complexes with TGF-β/activin-activated Smad2/3 3, 4 and with BMP-activated Smad1/5/8 5, 6 to regulate transcriptions of genes that are involved in the suppression of epithelial cell growth. 7, 8 Extensive evidence supports the role of the TGF-β signaling pathway in mammary carcinogenesis. 9 For example, mammary tumorigenesis is enhanced in transgenic mice with compromised TβRII function, 10 and TβRII expression is reduced in early and late stages of human breast cancer. 11, 12 In addition, many breast cancer cell lines have minimal response to the growth inhibitory effects of TGF-β, 13 and transfection of TβRII restored the growth inhibitory responses to TGF-β in MCF-7 breast cancer cell line. 14 Inactivation of the TGF-β signaling pathway has been well-established to be important in the carcinogenesis of pancreas, colon and ovary. 15 This is usually achieved through biallelic inactivation of the SMAD4 gene. In contrast, biallelic inactivation was rarely observed in breast cancer. Homozygous deletion of the SMAD4 locus was initially reported in MDA-MB-468 cells during the screening of eight breast cancer cell lines. 16 However, subsequent mutation screening of SMAD4 failed to identify any somatic point mutations in 54 primary breast tumors containing 18q allelic loss, 17 questioning the importance of SMAD4 biallelic inactivation in breast cancer. Since the frequency of SMAD4 homozygous deletion is high in other cancer types, we sought to revisit this issue and to develop a reliable method to evaluate homozygous deletion of SMAD4 in archived paraffin-embedded primary breast tumors. We have previously invented the "counting alleles" method which allowed the detection of single DNA template molecule in archived tissues. 18 By combining this method with quantitative real-time PCR (QPCR), we have developed countingalleles based quantitative PCR (CA-QPCR), an accurate method for quantifying the number of DNA molecules in laser-capture microdissected (LCM) samples. Application of CA-QPCR allowed us to complete an analysis of SMAD4 homozygous deletion in primary breast tumors and to demonstrate that the frequency of SMAD4 homozygous deletion is approximately 6% in infiltrative ductal carcinomas. All other breast cancer cell lines were purchased from the American Type Culture Collection (ATCC) (Manassas, VA) and were propagated according to the conditions recommended. Genomic DNA samples were isolated using the Blood & Cell Culture DNA Midi Kit from Qiagen (Valencia, CA), and total RNA was isolated from cytoplasm of cells using Qiagen's RNeasy Maxi Kit. 19 All primary tumors were early stage, lymph-node negative, invasive ductal adenocarcinomas (IDC) from the University Hospital and the General Hospital Saint-Augustinus, Antwerp, Belgium. 20 This study was approved by institution IRB.
MATERIALS AND METHODS

Cell
Quantitative real-time reverse transcription-PCR (RT-PCR). cDNA was prepared by reverse transcription with random primer (invitrogen), using 1 µg of total RNA extracted from breast cancer cell lines. Each PCR was carried out in triplicates in a 20-µl volume using iQ SYBR green supermix (Bio-Rad, cat# 170-8882) on the Bio-Rad iCycler. SMAD4 RT-PCR primers were 5'-GGTGAAGGTGATGTTTGGGTC-3' and 5'-CTTTGA-TGCTCTGTCTTGGGTA-3'. Standard curves for SMAD4 and glyceradehyde-3-phophate dehydrogenase (GAPDH) were generated, and gene expression levels of SMAD4 were normalized by a comparative threshold cycle method. Finally, a ratio was calculated comparing normalized gene expression values in cancer cell lines versus normal control cell lines, and standard deviations were calculated based on values from the triplicates.
Purification of DNA from archived tissues. Two sections were cut from each paraffin block and mounted on noncoated slides. The first one was cut at 5 microns, stained with hematoxylin and eosin, and routinely mounted. This section was used for the identification of tumor and normal cells from each sample. The second section was cut at 12 microns, stained with hematoxylin and eosin (H&E) and no coverslip was applied.
Tumor cells were laser-capture microdissected from this section. Briefly, H&E stained slides were dehydrated with xylene and dried in a Nalgene vacuum desiccator overnight (Fisher, cat# 08-642-5). Tumor cells were laser-captured onto the Arcturus CapSure MacroLCM caps (Arcturus, LCM0202) with PixCell ® IIe Laser Capture Microdissection (LCM) System. Microdissected tissue samples were treated with proteinase K (1 mg/ml proteinase K, QIAGEN, cat#19131, 1% Tween 20 in 10 mM Tris-1 mM EDTA, pH 8.0) at 37˚C for 16 hours. Proteinase K was inactivated at 95˚C for 10 min. Samples were directly used in CA-QPCR for DNA copy numbers analysis and in STS assays for SMAD4 homozygous deletion analysis.
Calibration of a DNA standard curve for QPCR. Counting alleles method was used to determine the number of DNA template molecules in a standard curve containing serial dilution of a control sample. 18 Specifically, genomic DNA was isolated from cells of a normal individual who is heterozygous for a single nucleotide polymorphic (SNP) marker, WIAF-1085. A 4-fold serial dilution of this control DNA was made and used as a standard curve. The amount of DNA template molecules in each dilution in the standard curve was determined by diluting a 2 µl aliquot into a PCR reaction mixture, which was then robotically distributed into many wells on a 384-well plate. The detection of different alleles of WIAF-1085 is carried out with SNP-specific molecular beacons (MBs) which were included in the PCR mixture to allow a single-step reaction setup. MBs are single-stranded DNA probes that have self-complementary ends and form therefore stemloop structures. They have a fluorescent tag at the 5' end and a quenching moiety at the 3' end. In the absence of the target, MBs are in a stem-loop form and the fluorescent signal is suppressed due to the close proximity of fluorophore and quencher. When hybridized to a complementary target sequence, molecular beacons change their conformation so that the fluorescent tag and quenching moiety are spatially separated, and the fluorescent signal can be detected via fluorometry. PCR primers and molecular beacons for WIAF-1085 were described in detail previously. 21 Quantitative real-time PCR were carried out using the same DNA standard curve in Bio-Rad iCycler using iQ SYBR green supermix (Bio-Rad, cat# 170-8882).
Statistical prediction of allele distribution in the "Counting Alleles" analysis. The "Counting Alleles" method robotically distributes a PCR reaction mixture into many wells on a plate. Since the DNA for the standard curve is heterozygous for WIAF-1085, it should contain equal amount of A and G alleles. Suppose n A alleles and n G alleles that are contained in the PCR reaction mixture are randomly distributed into w wells. The probability for a well attaining exactly x A alleles each well contains follows a binomial distribution (the number of trials is n and the success probability in each trial is1/w):
[Place equation here].
The same applies for G alleles. The probability of a well containing exclusively A alleles or G alleles (shown in red or green) is then given by:
The probability of a well containing a mix of A and G alleles (shown in yellow) is:
Thus the expected number of green (or red) wells is w* P red with a standard deviation of:
The expected number of yellow wells is w* P yellow with a standard deviation of:
If n = 40, w = 168, the expected number of green (or red) wells is 28 with a standard deviation of 3 and the expected number of yellow wells is 8 with a standard deviation of 2.
Smad4 Inactivation in Breast Cancers
STS markers for SMAD4 analysis in cancer cell lines and tumors.
Homozygous deletions of SMAD4 in cell lines and primary tumors were determined by the lack of PCR amplification products for the selected STS markers. Primer sequence, location and PCR product size for each STS were listed in Table 1 . STS markers for cancer cell line screening were approximately 200 bps in length. STS markers for screening primary tumors were approximately 100 bps in length.
Immunohistochemical analysis of Smad4 protein.
Immunohistochemical study was performed on 5-µm sections of paraffin-embedded, formalinfixed tissue. Sections were deparaffinized in xylene and rehydrated gradually through a series of alcohols. Slides were then washed twice in deionized water for 5 minutes each. Antigen retrieval was carried out by heating at 99˚C for 20 minutes in 10 mM sodium citrate buffer, pH 6.0~6.2. Sections were incubated in 3% hydrogen peroxide for inactivating endogenous peroxidase. To eliminate nonspecific staining, sections were incubated with 5% of normal horse serum at room temperature for 20 minutes. Slides were incubated with mouse monoclonal anti-Smad4 antibody (Clone B-8, 1:100. Santa Cruz Biotechnology, CA, U.S.A) overnight at 4˚C. A streptavidin-biotin-horseradish peroxidase detection system was used in accordance with manufacture's instruction (K0679, DAKA, CA, U.S.A) and then developed in fresh 3,3'-diaminobenzidine tetrahydrochloride solution (Sigma Chemical Co. St. Louis, MO) for 10 minutes or until the sections turned brown. Sections were then lightly counterstained with hematoxylin, dehydrated in graded alcohols, cleared in xylene and mounted using Permount mounting medium (Fisher Scientific Company, Fair Lawn, NJ). A known positive control (pancreatic cancer) and a universal monoclonal negative control (Dako, CA, USA) were run with the cases.
For the assessment of SMAD4, the immunoreactive score was determined by combining an estimate of the percentage of immunoreactive cells (quantity score) with an estimate of the staining intensity (intensity score). Staining quantity is scored as follows: no staining is 0, 1-9 of cells stained is scored as 1, 10-25 as 2, 26-50 as 3, and >50 as 4. Staining intensity is scored on a scale of 0-3 where 0 is no staining, 1 is weak, 2 is moderate and 3 is strong. The staining intensity score and staining quantity score are multiplied to give the IRS score. An IRS of 9-12 was considered strong immunoreactivity, 5-8 was moderate, and 0-4 was considered weak. We defined samples with moderate or strong SMAD4 expression as having an elevated SMAD4 expression.
RESULTS
SMAD4 homozygous deletion in SW527 breast cancer cell line. Thirtyone breast cancer cell lines were screened for homozygous deletions of SMAD4. Seven short tag sequence (STS) markers were selected from NCBI at the SMAD4 genomic locus, and PCR primers were designed for PCR amplification of each STS. As a positive control, we used MDA-MB468, a cell line derived from a patient with breast carcinoma, which has a homozygous deletion of the complete SMAD4 coding region. 16 As expected, amplification products for rs3829616, UniSTS:15242, rs948588 and UniSTS:88461 were not detectable in MDA-MB-468 due to the deletion of the entire Smad4 coding region (Fig. 1A, lane 1) . Amplification products for all seven markers were detectable in all other cell lines, except for rs3829616 and UniSTS:15242 in SW527 (Fig. 1A, lane 3) . Thus, SW527 appeared to contain a micro-deletion within the Smad4 gene, which comprised only the 5' end of the coding region. Since this deletion disrupts the 5' promoter region of SMAD4, it should interfere with transcription initiation of SMAD4. The expression of Smad4 in SW527 was evaluated by quantitative real-time PCR. SMAD4 expression was detected in all cell lines except for MDA-MB-468 and SW527 (Fig. 1B) . Therefore, homozygous deletions of SMAD4 in SW527 and MDA-MB-468 lead to complete elimination of SMAD4 expression.
The mechanism of homozygous deletion of Smad4 in both cell lines was also investigated. All cell lines were screened for LOH of chromosome 18q using the Homozygosity Mapping-of-Deletion Analysis (HOMOD) method. HOMOD uses highly polymorphic microsatellite markers (heterozygosity rate >0.70) and statistics to identify regions of deletion in unmatched cancer cell lines. 22 Regions of loss was defined by the presence of an extended region of homozygosity at more than 5 adjacent highly polymorphic markers with a statistical significant probability (p < 0.01). Eight polymorphic markers with a heterozygosity of at least 0.75 were chosen for chromosome 18q and these markers were spaced out at approximately 6 MB per marker. Allelic loss were not detect in the fourteen cell lines as most of the markers were heterozygous. In eleven cell lines which include MDA-MB468 and SW527, all informative polymorphic markers were homozygous (Supplemental Fig. 1 ). Since this is a statistically unlikely event given the rate of heterozygosity for selected markers, LOH of 18q in these cell lines probably involve the entire chromosome arm. Therefore, homozygous deletions of the Smad4 locus in both cell lines were due to one micro-deletion in the Smad4 locus in one allele and loss of heterozygosity of the other allele. Accurate DNA quantitation in laser-captured samples. To assess SMAD4 homozygous deletion in laser-capture microdissected samples, we developed a quantitative PCR method to assess the number of DNA template molecules recovered by this method. Briefly, DNA recovery from archived samples was determined by quantitative real-time PCR method and comparison/calibration against a DNA standard curve containing serial dilution of a control sample with approximately 5, 20, 80, 320 and 1280 DNA molecules. One example of the DNA standard curve for CA-QPCR is shown in Figure 2 using WAIF-1085 SNP markers and genomic DNA isolated from a normal individual who is heterozygous for this marker. DNA concentration in the calibration standard was determined empirically using the "counting alleles" method. 23 Genomic DNA from normal human DNA was initially diluted in 4-fold dilutions, and lowest concentration was determined to contain approximately 5 copies of haploid genome equivalent. To verify the actual number of DNA molecules in the standards, we used the original counting allele method on the three lowest dilutions (with approximately 5, 20, and 80 DNA molecules). Three reaction mixtures were made to contain approximately 5, 20 or 80 copies of haploid genome equivalent in 144, 288 or 504 µl, respectively. Aliquots of 3 µl were robotically distributed to 48, 96 or 168 wells in a 384-well plate (Fig. 2A) . The wells in which PCR amplifications occurred are shown in green, red or yellow (indicates mix of green and red). PCR products were detected via fluorometry with SNP-specific molecular beacons (MB) for either A alleles (SNP A, green) or G alleles (SNP G, Red). The distribution patterns of both SNP alleles after PCR are shown in Figure 2A . For example, "Counting Alleles" analysis of 80 DNA molecules in 168 wells (in rows 1-7, Fig. 2A ) resulted in 28 wells containing A alleles, 26 with G alleles and 8 with a mix of both alleles. This pattern fits both the theoretic prediction and computer simulation model for the random distributions of 80 DNA molecules (approximately 40 A alleles and 40 G alleles) in 168 wells (see Material and Methods). The methods predicted a mean of 28 wells containing exclusively A Alleles and G alleles respectively with a standard deviation of 3, and a mean of 8 wells containing a mixture of A and G Alleles with a standard deviation of 2. Similar predicted distribution patterns were observed for DNA standards with 20 (rows 8-11) and 5 (rows 12 and 13) molecules. Therefore, the initial numbers of DNA template molecules estimated in the calibration standard were confirmed by the "counting alleles" method.
We also observed a consistent relationship between PCR cycle numbers and DNA copy numbers with our QPCR conditions (correlation coefficient > 0.95), and we have determined that the detection limit of our assay is five haploid genome equivalent (Fig. 2B) . Utilization of this standard curve in quantitative PCR allowed us to efficiently and reliably determine DNA yield by the number of template molecules.
SMAD4 homozygous deletion analysis in primary breast tumors. We have previously used "counting alleles" method to analyze early stage, node-negative infiltrative ductal breast carcinomas and identified 40 cases with LOH on chromosome 18q. 24 Twenty-four cases had sufficient left-over materials for SMAD4 homozygous deletion analysis. LCM was used to isolated pure tumor cells, and an example was shown in Figure 3A . Approximately 2,500 cells were captured for each sample on average. Genomic DNA was extracted by proteinase K treatment, and DNA yield was determined by comparing the amount of DNA in 2 µl of each sample preparation with the DNA standard described above using CA-QPCR. This analysis was carried out in duplicates for each sample to control for experimental variability. DNA recoveries from these samples were summarized in Table 2 . Average DNA recovery was approximately 2000 DNA template molecules per sample.
To ensure robust PCR amplification of DNA isolated from archived tissue, small PCR products (~100-bp in length) were designed for each of the six STS markers used for SMAD4 homozygous deletion analysis (Table 1) . We used the same PCR amplification condition as the "counting alleles" method which was sufficient and robust for single-molecule amplification in all markers used in this study. At least 20 DNA template molecules were included in each amplification reaction, and each marker was tested in duplicates. The loss of at least two contiguous STS markers was necessary for determining SMAD4 homozygous deletion in each sample. We also determine the rate of random PCR failures of these markers using DNA isolated from LCM sample, and the rate of non-contiguous PCR failure varied from zero to 8% (Table 3) .
Three homozygous deletions of SMAD4 were identified in infiltrative ductal carcinomas (Fig. 3B) . BT17 contained homozygous deletions of three consecutive markers (rs948588, rs4318301 and rs2510000) in the middle of the SMAD4 coding region. BT40 contained homozygous deletion of rs2427780 and rs2509999 which comprised of the 3' region of SMAD4 including exon 8. Since we have exhausted all archived material for this sample, we could not test markers 3' downstream from rs2509999. Thus, the exact size of this deletion in BT40 is unknown. BT54 contained homozygous deletion of rs948588 and rs4318301, both of which located within intron 8. To determine the boundary of this deletion, we also designed PCR primers to amplify exon 8 and exon 9 in BT54 (Table 1 , exon 8-STS and exon 9-STS). Neither exon was deleted in BT54 (data not shown). Therefore, the microdeletion in BT54 did not include any coding sequence in Smad4.
Immunohistochemical analysis of Smad4 protein in primary tumors. To determine whether all three homozygous deletions of SMAD4 led to alteration of Smad4 protein expression, we evaluated Smad4 protein expression in these tissue samples with immunohistochemical analysis. Smad4 immunoreactivity in both invasive ductal carcinomas and associated adjacent normal breast tissues was characteristically cytoplasmic and granular, with few cases showing nuclear staining (6 normal breast tissue cases and 3 cancer cases). In normal breast cases, SMAD4 expression was located in the cytoplasm of the epithelial and myoepithelial cells but was rarely observed in neighboring stromal cells. In invasive ductal carcinoma, BT17 and BT40 did not express Smad4 as expected (Fig. 3C) . BT54, on the other hand, have 
DISCUSSION
Previous genetic analyses of SMAD4 in primary tumors were limited to mutation screening for point mutations and insertions/ deletions of a few bases. Since homozygous deletion was a preferred mechanism for SMAD4 inactivation in other cancer types and was observed twice in breast cancer cell lines, we sought to develop an accurate method to evaluate the frequency of SMAD4 homozygous deletion in paraffin-embedded archived primary tumors. As these specimens contain a mixture of different tissues, contaminating DNA from normal tissues can easily mask homozygous deletion of SMAD4 in tumor cells. This obstacle can be overcome with the use of laser-capture microdissection (LCM) to obtain pure tumor cells. One technical problem associated with LCM is that the amount of recovered DNA is usually very low and therefore difficult to quantify with existing techniques. Some studies quantified the number of micro-dissected cells as a measure to ensure sufficient and equal DNA recovery in archived samples, 25 but the DNA concentrations are still not measured directly. If limited amounts of overall DNA are recovered, only a few template molecules may be included in the PCR, and over-or under-amplification of these molecules by chance alone can easily lead to experimental variability and mis-diagnosis of gain or loss in certain genomic region. 26 We have previously developed the "counting alleles" method which determines how many individual maternal and paternal alleles are present in archived specimens. 18 Briefly, genomic DNA is isolated from the microdissected tumor and autologous normal tissues and added to separate PCR mixtures which are robotically distributed to the wells of a 384-well plate. The concentration of genomic DNA of each sample is determined in advance so that there is on average less than one DNA molecule added per well. PCR product will only form in wells that contained template DNA derived from either the maternal or paternal allele. This method was initially developed to measure allelic imbalance in archived tissues, but it also quantifies the total number of parental alleles present in a sample by counting the number of wells which gave PCR products derived from each of the parental alleles. Therefore, it can be used to measure DNA on molecular level. A practical drawback of this method was that it required hundreds of reactions per sample and was not a cost-efficient method to measure DNA concentration. To overcome this issue, we have now developed a "Counting Allele"-based quantitative PCR assay (CA-QPCR) for such measurement. Specifically, DNA recovery from archived samples was determined by quantitative real-time PCR method and comparison/calibration against a DNA standard curve containing serial dilution of a control sample with known amount of DNA molecules. Our method can reliable detect as few as 5 copies of WIAF-1085 in archived specimens. One potential complication of this measurement is that the genomic regions surrounding WAIF-1085 may be amplified due to chromosome polyploidy, thus leading to over-estimation of overall DNA templates. To offset this potential over-estimation, we decided to include at least 20 DNA template molecules (as measured by WIAF-1085) in the homozygous deletion analysis for amplification of SMAD4 genetic markers, realizing that the actual number of DNA template included in such analysis may vary from 5 copies to 40 copies (in case of allelic deletion of WIAF-1085). Our amplification condition was robust as random PCR failures were infrequently observed in LCM samples ( Table 3) .
The failure of PCR amplification in STS assay may also be due to polymorphisms resided in DNA sequences for the amplification primers. Two strategies were used to minimize such artifacts. First, STS markers used for archived specimens analysis were selected from genomic regions where SNP analyses were extensively characterized and only the regions without SNPs were used as PCR priming sites. For example, rs948588 contained a SNP with an estimated heterozygosity rate of 0.95. Nevertheless, no SNP was identified in the priming sequence for rs948588. Second, amplification failures of two consecutive STS markers are necessary to score a homozygous deletion. Therefore, PCR failures of consecutive STS markers in our assay are due to deletion but not polymorphisms in PCR priming site.
The identification of four homozygous deletions in the coding region of the SMAD4 gene in two breast cancer cell lines and two primary infiltrative ductal carcinomas indicated that biallelic inactivation of SMAD4 play an important role in the carcinogenesis of a small percentage of breast cancers. Since the frequency of 18q allelic imbalance is 68% in IDC, 24 we estimate the overall frequency of SMAD4 homozygous deletion in IDC is approximately 6%. The low deletion frequency is consistent with a previous immunohistochemistry analysis of SMAD4 in breast tumor tissue microarrays, which identified 8 samples with no SMAD4 expression in 371 ductal carcinomas. 27 In addition, there was a trend towards longer survival times in patients with Smad4 negative tumors. 28 It is important to point out that homozygous deletion of SMAD4 is not the only process for Smad4 inactivation in breast cancer even though point mutations and promoter hypermethylation of SMAD4 was rarely observed in breast cancer. Recently, Jacob et al identified a 9 base pair in-frame deletion of SMAD4 (amino acids 49-51) in HCC-1428 that did not affect the SMAD4 message but the level of Smad4 protein. 29 Therefore, proteasome-mediated protein degradation may also play a role in Smad4 inactivation.
Interestingly, the role of the TGF-β signaling pathway seems to be cell-type dependent in breast epithelial cells. TGF-β signaling appears to inhibit proliferation in ductal epithelial cells and to induce apoptosis in the lobular cells. 30 Therefore, it is not clear whether the inactivation of this signaling pathway plays the same role in breast cancer formation for both cell types. Previous immunohistochemistry analysis observed SMAD4 expression in all 85 lobular Smad4 Inactivation in Breast Cancers carcinomas, 30 suggesting that the inactivation of SMAD4 may not be important in the carcinogenesis of the breast lobular cells. Our findings also suggest that other components of the TGFβ signaling pathway may be susceptible to genetic/epigenetic alterations during mammary ductal carcinogenesis. SMAD2 was homozygously inactivated in some colorectal tumors, 31 and Xie et al. have identified 25 primary breast tumors with negative Smad2 expression by immunohistochemistry in 369 IDC samples. These tumors may contain genetic/epigenetic inactivation of Smad2. 27 TβR-I receptor gene may be another target. Chen et al have previously identified two missense mutations in TβR-I receptor gene in 31 breast primary tumors. 32 A systematic evaluation of the genetic and epigenetic status of these genes should be informative for the role of TGFβ signaling pathway in the formation of infiltrative ductal carcinomas.
